June 30, 2017
Lucid Pharma LLC is voluntarily recalling nearly 70,000 bottles of venlafaxine hydrochloride extended-release capsules USP, 75 mg, due to pharmacist complaints about melted capsules, according to the June 7, 2017, US Food and Drug Administration (FDA) Enforcement Report.
The recall spans 44,168 30-count bottles from lot V17516045-A (Exp. 8/18) and 24,960 90-count bottles from lot V17516047-A (Exp. 9/18). The affected lots were distributed throughout the United States.
Lucid Pharma initiated the recall June 1, 2017. The FDA categorized it class II June 16, 2017, indicating the affected capsules may cause reversible adverse health consequences that are not likely to be serious.
Venlafaxine hydrochloride is a prescription-only selective serotonin and norepinephrine reuptake inhibitor for the treatment of depression, anxiety, and panic disorder.